SCHEMBL4838858

SCHEMBL4838858

CC(C)(C)OC(=O)CC(CC(=O)NOC(c1ccccc1)(c1ccccc1)c1ccccc1)C(=O)NCCc1ccc(-c2ccccn2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 2/20 0.39
ESRRG P62508 1/20 0.39
TRPV1 Q8NER1 1/20 0.38
CA9 Q16790 1/20 0.37
HCAR2 Q8TDS4 1/20 0.37
NR1H2 P55055 2/20 0.37
UGT1A1 P22309 3/20 0.36
MLNR O43193 1/20 0.36
NR1I2 O75469 1/20 0.36
SLCO2B1 O94956 1/20 0.36
ABCB11 O95342 1/20 0.36
ABCB1 P08183 1/20 0.36
CCKAR P32238 1/20 0.36
OPRK1 P41145 1/20 0.36
GHSR Q92847 1/20 0.36
SLCO1B3 Q9NPD5 1/20 0.36
ABCG2 Q9UNQ0 1/20 0.36
SLCO1B1 Q9Y6L6 1/20 0.36
MMP1 P03956 2/20 0.36
MMP3 P08254 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4839942 0.90 CA2 (0.45) CA2ESRRGCA9NR1H2MMP1
SCHEMBL4840798 0.87 MMP2 (0.45) CA2ESRRGCA9NR1H2MMP1
SCHEMBL4841261 0.85 ABCB1 (0.46) CA2ESRRGCA9ABCB1ABCG2
SCHEMBL4840314 0.85 CA2 (0.40) CA2ESRRGCA9NR1H2MMP1
SCHEMBL4835699 0.83 SMN1; SMN2 (0.43) CA2CA9NPC1RAB9A
SCHEMBL4831392 0.82 CA2 (0.43) CA2ESRRGCA9MMP1MMP3
SCHEMBL4886128 0.82 KMT2A (0.45) CA2TRPV1CA9MMP3
SCHEMBL4831283 0.81 CA2 (0.49) CA2CA9NR1H2L3MBTL1KCNH2
SCHEMBL4838875 0.80 TRPV1 (0.34) CA2TRPV1CA9UGT1A1MLNR
SCHEMBL4838164 0.79 NPC1 (0.48) CA2CA9MMP1MMP3L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7365091-B2 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX ENOBIA PHARMA (CA) 2008-04-29 US disclosed
US-20060287280-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX ENOBIA PHARMA (CA) 2006-12-21 US disclosed
US-7105539-B2 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex ENOBIA PHARMA (CA) 2006-09-12 US disclosed
US-20060135480-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex ENOBIA PHARMA (CA) 2006-06-22 US disclosed
EP-1572645-A2 DERIVATIVES OF SUCCINIC AND GLUTARIC ACIDS AND ANALOGS THEREOF USEFUL AS INHIBITORS OF PHEX Enobia Pharma Inc. (CA) 2005-09-14 EP disclosed
US-20040186301-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex BIOMEP INC. 2004-09-23 US disclosed
WO-2004050620-A2 DERIVATIVES OF SUCCINIC AND GLUTARIC ACIDS AND ANALOGS THEREOF USEFUL AS INHIBITORS OF PHEX ENOBIA PHARMA (CA) 2004-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060287280-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX GLS, SUCNR1, PGD CA2 333/4885ESRRG 2070/4885TRPV1 4650/4885
US-20040186301-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex GLS, SUCNR1, PGD CA2 344/4885ESRRG 2129/4885TRPV1 4672/4885
US-20060135480-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex GLS, SUCNR1, GCDH CA2 366/4885ESRRG 2175/4885TRPV1 4685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.